.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
US Army
McKinsey
QuintilesIMS
AstraZeneca
Merck
Cerilliant
Fuji
Healthtrust
Novartis

Generated: November 22, 2017

DrugPatentWatch Database Preview

PERRIGO NEW YORK Company Profile

« Back to Dashboard

What is the competitive landscape for PERRIGO NEW YORK, and when can generic versions of PERRIGO NEW YORK drugs launch?

PERRIGO NEW YORK has sixty-one approved drugs.

There is one US patent protecting PERRIGO NEW YORK drugs.

There are five patent family members on PERRIGO NEW YORK drugs in five countries and seventeen supplementary protection certificates in nine countries.

Summary for PERRIGO NEW YORK

International Patents:5
US Patents:1
Tradenames:30
Ingredients:29
NDAs:61
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo New York
TRIAMCINOLONE ACETONIDE
triamcinolone acetonide
CREAM;TOPICAL086413-001Approved Prior to Jan 1, 1982ATRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
PERMETHRIN
permethrin
CREAM;TOPICAL076369-001Apr 21, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
NITROFURAZONE
nitrofurazone
OINTMENT;TOPICAL084968-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
TRIPLE SULFA
triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole)
CREAM;VAGINAL087285-001Nov 15, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
FLUOCINOLONE ACETONIDE
fluocinolone acetonide
CREAM;TOPICAL086811-001Mar 4, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
AMMONIUM LACTATE
ammonium lactate
CREAM;TOPICAL075774-001May 1, 2002ABRXNoYes► Subscribe► Subscribe► Subscribe
Perrigo New York
HYDROCORTISONE
hydrocortisone
OINTMENT;TOPICAL084969-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
DESONIDE
desonide
CREAM;TOPICAL017010-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Perrigo New York
FLUOCINOLONE ACETONIDE
fluocinolone acetonide
CREAM;TOPICAL086810-001Mar 4, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
CREAM, AUGMENTED;TOPICAL076592-001Dec 9, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Perrigo New York Drugs

Country Document Number Estimated Expiration
Canada2259764► Subscribe
Israel123143► Subscribe
European Patent Office0933081► Subscribe
Spain2165723► Subscribe
Germany69900561► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Perrigo New York Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
60031Netherlands► SubscribePRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0002Belgium► SubscribePRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
C/GB97/005United Kingdom► SubscribePRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
C/GB02/033United Kingdom► SubscribePRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Julphar
Federal Trade Commission
US Army
Dow
Cerilliant
Mallinckrodt
QuintilesIMS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot